Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Monoclonal Antibodies For COVID Suffer Access Problems Due To Limited Infusion Reimbursement

Executive Summary

Unused supply for the Lilly and Regeneron therapies has policymakers considering Medicare payment changes for providers managing outpatient infusion, but those may require legislation. National Academies of Sciences, Engineering and Medicine committee considers the ‘paradox of unused supply with a relatively scarce product’ and tries to dissect the challenges that may be contributing to the unexpected lack of take-up for the mABs.

You may also be interested in...



Medicare More Than Doubles Payment Rate For COVID Monoclonal Antibody Administration At Home

Regeneron and Eli Lilly have seen limited uptake for their COVID treatments; CMS payment increase addresses concerns that inadequate reimbursement has hampered use of the monoclonal antibody drugs.

Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?

Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.

Stock Watch: Lilly’s Fourth Quarter − Pandemic Benefits And Challenges

Lilly’s fourth-quarter results included windfalls, not just from the pandemic but from seasonal wholesaler buying patterns that were intensified by the pandemic and raise a high bar for subsequent quarters.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel